Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs - A prospective study

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 11, 2010, Pages 1340-1346

  Di Giacomo, T B ^a   Hussein, T P ^a   Souza, D G ^a   Criado, P R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticoagulation; Heparin; Livedoid vasculopathy; Thrombophilia; Warfarin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; CHLOROQUINE; COLCHICINE; CYCLOSPORIN; DALTEPARIN; DIOSMIN; ENOXAPARIN; FIBRINOGEN; HEPARIN; HESPERIDIN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; NICOTINIC ACID; PENTOXIFYLLINE; PREDNISONE; PROTEIN C; PROTEIN S; VITAMIN B COMPLEX; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; LEG ULCER; LIVEDO RETICULARIS; MALE; PAIN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; PUVA; REMISSION; SKIN BLOOD VESSEL DISORDER; THROMBOPHILIA; WOUND HEALING;

EID: 78649727088     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03646.x     Document Type: Article

References (38)

1. Bard JW, Winkelmann RK. Livedo vasculitis: Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967; 96: 489-499.
2. Milian G. Les atrophies cutane'es syphilitiques. Bull Soc Franc Derm Syph 1929; 36: 865-871.
3. Feldaker M, Hines EA Jr, Kierland RR. Livedo reticularis with ulcerations. Circulation 1956; 13: 196-216.
4. Winkelmann RK, Schroeter AL, Kierland RR, Ryan TM. Clinical studies of livedoid vasculitis (segmental hyalinizing vasculitis). Mayo Clin Proc 1974; 49: 746-750.
5. McCalmont CS, McCalmont TH, Jorizzo JL et al. H. Livedo vasculitis: Vasculitis or thrombotic vasculopathy? Clin Exp Dermatol 1992; 17: 4-8.
6. Stevanovic DV. Atrophie blanche: A sign of dermal blood occlusion. Arch Dermatol 1974; 109: 858-862.
7. Shornick JK, Nicholes BK, Bergstresser PR, Gilliam JN. Idiopathic atrophie blanche. J Am Acad Dermatol 1983; 8: 792-798.
8. Pizzo SV, Murray JC, Gonias SL. Atrophie blanche: A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med 1986; 110: 517-519.
9. Hegemann B, Helmbold P, Marsch WC. Livedoid vasculitis with ulcerations: The role of antithrombin III deficiency and its therapeutic consequences. Arch Dermatol 2002; 138: 841-842.
10. Hairston BR, Davis MDP, Pittelkow MR, Ahmed I. Livedoid vasculopathy. further evidence for procoagulant pathogenesis. Arch Dermatol 2006; 142: 1413-1418.
11. Deng A, Gocke CD, Hess J et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006; 142: 1466-1469.
12. Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142: 75-78.
13. Calamia KT, Balabanova M, Perniciaro C, Walsh JS. Livedo (livedoid) vasculitis and the factor V Leiden mutation: Additional evidence for abnormal coagulation. J Am Acad Dermatol 2002; 46: 133-137.
14. Grasland A, Crickx B, Blanc M et al. Livedoid vasculopathy associated with anticardiolipin antibodies. Ann Med Interne 2000; 151: 408-410.
15. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351: 268-277.
16. Hiltenbrand C, Didier A, Lantrade P et al. Long-term administration of calcium-heparin in thromboembolism (author's transl). Ann Med Interne (Paris) 1980; 131: 406-409.
17. Gray HR, Graham JH, Johnson W, Burgoon CF Jr. Atrophie blanche: Periodic painful ulcers of lower extremities: A clinical and histopathogical entity. Arch Dermatol 1966; 93: 187-193.
18. Tran MD, Becherel PA, Cordel N et al. "Idiopathic" white atrophy [in French]. Ann Dermatol Venereol 2001; 128: 1003-1007.
19. Mimouni D, Ng PP, Rencic A et al. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol 2003; 148: 789-794.
20. Clive Landis R. Protease activated receptors: Clinical relevance to hemostasis and inflammation. Hematol Oncol Clin N Am 2007; 21: 103-113.
21. Khenifer S, Thomas L, Balme B et al. Livedoid vasculopathy: Thrombotic or inflammatory disease? Clin Exp Dermatol 2009 Oct 23 [Epub ahead of print].
22. Salomon O, Steinberg DM, Zivelin A et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
23. Biedermann T, Flaig MJ, Sander CA. Livedoid vasculopathy in a patient with factor V mutation (Leiden). J Cutan Pathol 2000; 27: 410-412.
24. Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: A manifestation of the antiphospholipid syndrome? Br J Dermatol 1999; 140: 131-135.
25. Grob JJ, Bonerandi JJ. Thrombotic skin disease as a marker of the anticardiolipina syndrome: Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity. J Am Acad Dermatol 1989; 20: 1063-1069.
26. Tait RC, Walker ID, Reitsma PH et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87-93.
27. Gladson CL, Scharrer I, Hach V et al. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
28. Pabinger I, Brucker S, Kyrle PA et al. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3: 547-553.
29. Baccard M, Vignon-Pennamen MD, Janier M et al. L. Livedo vasculitis with protein C system deficiency. Arch Dermatol 1992; 128: 1410-1411.
30. Boyvat A, Kundakci N, Babikir MO, Gurgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000; 143: 840-842.
31. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2106.
32. Gibson GE, Li H, Pittelkow MR. Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol 1999; 40: 279-281.
33. Jetton RL, Lazarus GS. Minidose heparin therapy for vasculitis of atrophie blanche. J Am Acad Dermatol 1983; 8: 23-26.
34. Davis MD, Wysokinski WE. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin. J Am Acad Dermatol 2008; 58: 512-515.
35. Kavala M, Kocaturk E, Zindanci I et al. A case of livedoid vasculopathy associated with factor V Leiden mutation: Successful treatment with oral warfarin. J Dermatol Treat 2008; 19: 121-123.
36. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med 2003; 139: 893-900.
37. Lee SS, Ang P, Tan SH. Clinical profile and clinical outcome of livedoid Vasculopathy: A case series. Ann Acad Med Singap 2003; 32: 835-839.
38. Francés C, Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol 2004; 140: 1011.